Over the past year, Plymouth Meeting-based Inovio Pharmaceuticals has reduced its workforce by 16 percent to preserve cash as it waits for the Food and Drug Administration ruling on its new drug application, writes John George for the Philadelphia Business Journal.
The FDA will determine by October 30 whether INO-3107, an experimental therapy from Inovio Pharmaceuticals, can be approved to treat recurrent respiratory papillomatosis, or RRP, in adults.
RRP is a rare chronic respiratory disorder marked by wart-like growths, known as papillomas, that develop in the airway and can interfere with speaking, swallowing, and breathing.
In 2025, Inovio Pharmaceuticals focused on conserving cash while awaiting discussions with the FDA about the approval process, according to CEO Jacqueline Shea. The company scaled back projects and eliminated roles that did not directly support the drug candidate’s path to approval, resulting in 22 job cuts and other cost-saving measures.
As of March 11, Inovio Pharmaceuticals employed 112 full-time workers, down from 134 on February 14, 2025. The reductions affected both product research and administrative roles and helped lower general and administrative expenses from $37 million in 2024 to $32.7 million last year.
Read more about Inovio and its trimmed workforce in the Philadelphia Business Journal.
_____
Editor’s Note: This post was originally published on MONTCO.Today in March 2026.
